Genome & Company (KOSDAQ:314130)

South Korea · Delayed Price · Currency is KRW

3,480.00

-145.00 (-4.00%)

At close: Jul 20, 2026

12.26% (1Y)

Market Cap	163.77B +69.9%
Revenue (ttm)	24.02B -19.5%
Net Income	-5.71B
EPS	-177.15
Shares Out	45.18M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	162,569
Open	3,510.00
Previous Close	3,625.00
Day's Range	3,390.00 - 3,600.00
52-Week Range	2,440.00 - 10,180.00
Beta	0.40
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About Genome & Company

Genome & Company, a clinical stage biotechnology company, researches and develops novel-targeted immuno-oncology therapeutics in the field of immuno-oncology, skin diseases, and autism in South Korea, Asia, Europe, South America, North America, and internationally. Its lead product candidate is GEN-001, an oral microbiome therapeutic candidate developed to have immune modulating activities. The company also develops GEN-501 targeting the non-responders of Dupilumab drugs with atopic skin diseases; and GENA-104 for the treatment of solid tumors,... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2015

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 314130

Full Company Profile

Financial Performance

In 2025, Genome & Company's revenue was 24.59 billion, a decrease of -11.38% compared to the previous year's 27.74 billion. Losses were -6.43 billion, -68.04% less than in 2024.

Financial Statements